Nisa Investment Advisors LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.7% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 1,007,940 shares of the company’s stock after purchasing an additional 16,684 shares during the period. Johnson & Johnson makes up approximately 1.3% of Nisa Investment Advisors LLC’s holdings, making the stock its 8th largest position. Nisa Investment Advisors LLC’s holdings in Johnson & Johnson were worth $139,267,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Financial Gravity Wealth Inc. acquired a new position in Johnson & Johnson in the 1st quarter valued at approximately $105,000. Selective Wealth Management acquired a new position in Johnson & Johnson in the 3rd quarter valued at approximately $105,000. WP Advisors LLC acquired a new position in Johnson & Johnson in the 2nd quarter valued at approximately $108,000. FNY Investment Advisers LLC acquired a new position in Johnson & Johnson in the 2nd quarter valued at approximately $117,000. Finally, Fusion Family Wealth LLC raised its holdings in Johnson & Johnson by 621.4% in the 2nd quarter. Fusion Family Wealth LLC now owns 1,010 shares of the company’s stock valued at $123,000 after acquiring an additional 870 shares in the last quarter. 66.23% of the stock is owned by institutional investors and hedge funds.
JNJ has been the subject of several recent research reports. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a report on Tuesday, November 20th. HC Wainwright reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, October 17th. Credit Suisse Group set a $149.00 price target on Johnson & Johnson and gave the company a “buy” rating in a report on Sunday, October 14th. ValuEngine raised Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Thursday, December 13th. Finally, Morgan Stanley cut their price target on Johnson & Johnson from $153.00 to $130.00 and set an “equal weight” rating for the company in a report on Wednesday, January 2nd. Three analysts have rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $140.89.
In related news, CAO Ronald A. Kapusta sold 3,643 shares of the stock in a transaction that occurred on Thursday, December 13th. The stock was sold at an average price of $147.31, for a total transaction of $536,650.33. Following the sale, the chief accounting officer now directly owns 13,641 shares in the company, valued at approximately $2,009,455.71. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO Ronald A. Kapusta sold 8,441 shares of the stock in a transaction that occurred on Thursday, November 8th. The stock was sold at an average price of $145.15, for a total value of $1,225,211.15. Following the sale, the chief accounting officer now owns 17,284 shares in the company, valued at $2,508,772.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 514,187 shares of company stock worth $74,951,528. 0.22% of the stock is owned by corporate insiders.
Shares of JNJ opened at $129.96 on Wednesday. Johnson & Johnson has a 1 year low of $118.62 and a 1 year high of $148.99. The company has a quick ratio of 1.40, a current ratio of 1.72 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $342.96 billion, a PE ratio of 17.80, a P/E/G ratio of 1.89 and a beta of 0.72.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.02. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The business had revenue of $20.35 billion during the quarter, compared to analysts’ expectations of $20.05 billion. During the same period in the prior year, the firm posted $1.90 EPS. Johnson & Johnson’s quarterly revenue was up 3.6% compared to the same quarter last year. As a group, equities research analysts expect that Johnson & Johnson will post 8.16 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 12th. Investors of record on Tuesday, February 26th will be given a dividend of $0.90 per share. The ex-dividend date of this dividend is Monday, February 25th. This represents a $3.60 dividend on an annualized basis and a yield of 2.77%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.
Johnson & Johnson announced that its board has approved a share buyback program on Monday, December 17th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 1.5% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
See Also: Reverse Stock Split
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.